Incyte (STU:ICY) Preferred Dividends : €0 Mil (TTM As of Mar. 2025)

View and export this data going back to 1993. Start your Free Trial

What is Incyte Preferred Dividends?

Preferred dividend is a dividend that is accrued and paid on a company's preferred shares. Incyte's preferred dividends for the three months ended in Mar. 2025 was €0 Mil. Its preferred dividends for the trailing twelve months (TTM) ended in Mar. 2025 was €0 Mil.

Incyte Preferred Dividends Historical Data

The historical data trend for Incyte's Preferred Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Preferred Dividends Chart

Incyte Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Preferred Dividends

Get a 7-Day Free Trial

Incyte Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Preferred Dividends	Get a 7-Day Free Trial															-	-	-	-	-

Incyte Preferred Dividends Calculation

A dividend that is accrued and paid on a company's preferred shares.

Incyte (STU:ICY) Preferred Dividends Explanation

In the event that a company is unable to pay all dividends, claims to preferred dividends take precedence over claims to dividends that are paid on common shares.

Preferred Dividends for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0 Mil.

Incyte Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (STU:ICY) » Definitions » Preferred Dividends

Comparable Companies

Traded in Other Exchanges

INCY:USA INCY:Mexico 1INCY:Italy 0J9P:UK ICY:Germany

Address

1801 Augustine Cut-Off, Wilmington, DE, USA, 19803

Website

https://www.incyte.com

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Incyte Headlines

No Headlines